The Covid-19 vaccine developed by Moderna has today been given regulatory approval for supply by the Medicines and Healthcare products Regulatory Agency (MHRA).
This follows a thorough and rigorous assessment by the MHRA’s teams of scientists, including advice from the independent Commission on Human Medicines, which reviewed in-depth all the data to ensure this vaccine meets the required standards of safety, quality and effectiveness.
This is the third COVID-19 vaccine to be approved for use by the MHRA and is the second mRNA vaccine (the Pfizer/BioNTech vaccine approved in December 2020 is also an mRNA vaccine).
MHRA Chief Executive Dr June Raine said:
“Today’s approval brings more encouraging news to the public and the healthcare sector. Having a third Covid-19 vaccine approved for supply following a robust and thorough assessment of all the available data is an important goal to have achieved and I am proud that the agency has helped to make this a reality.
“The progress we are now making for vaccines on the regulatory front, whilst not cutting any corners, is helping in our global fight against this disease and ultimately helping to save lives. I want to echo that our goal is always to put the protection of the public first.
“Once in use, all Covid-19 vaccines are continually monitored by the MHRA. This ensures that the benefits in protecting people against Covid-19 continue to far outweigh any potential side-effects. Meantime, even if you have had a vaccine it is vital that everyone follows the national lockdown restrictions and remembers ‘stay alert, protect the NHS and save lives’ at all times.”
Professor Sir Munir Pirmohamed, Chair of the Expert Working Group of the Independent Commission on Human Medicines said:
“We are delighted to be able to give a positive recommendation for the Moderna vaccine which will help in the roll-out of the Covid-19 vaccination programme.
“As with all the Covid-19 vaccine data we have seen to date, we have ensured a robust and thorough safety assessment has been carried out with the independent experts that sit on this group.”
This article is being shared under the Open Government Copyright licence.
